- Home
- GRTS
GRTS
Gritstone bio Inc.
as 07-26-2024 4:00pm EST
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, and CORAL, among others.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 72.6M | IPO Year: | 2018 |
| Target Price: | $4.75 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.52 - $3.33 | Next Earning Date: | 08-07-2024 |
| Revenue: | $15,645,000 | Revenue Growth: | 2.95% |
| Revenue Growth (this year): | -3.08% | Revenue Growth (next year): | -20.07% |
Stock Insider Trading Activity of Gritstone bio Inc. (GRTS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Economides Vassiliki | GRTS | EVP, CHIEF FINANCIAL OFFICER | May 15 '24 | Sell | $0.75 | 13,749 | $10,288.38 | 262,437 | SEC Form 4 |
| Hawryluk Matthew | GRTS | EVP, CHIEF BUSINESS OFFICER | May 15 '24 | Sell | $0.75 | 9,259 | $6,928.51 | 313,931 | SEC Form 4 |
| Allen Andrew R | GRTS | PRESIDENT AND CEO | May 15 '24 | Sell | $0.75 | 24,263 | $18,156.00 | 985,360 | SEC Form 4 |
| Jones Erin | GRTS | EVP, CHIEF OPERATING OFFICER | May 15 '24 | Sell | $0.75 | 13,749 | $10,288.38 | 359,293 | SEC Form 4 |
| Jooss Karin | GRTS | SEE REMARKS | May 15 '24 | Sell | $0.75 | 13,749 | $10,288.38 | 683,526 | SEC Form 4 |
Latest Gritstone bio Inc. News
GRTS Breaking Stock News: Dive into GRTS Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
GlobeNewswire
17 days ago
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
Simply Wall St.
3 months ago
Gritstone bio First Quarter 2024 Earnings: Misses Expectations
GlobeNewswire
3 months ago
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
3 months ago
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024
GlobeNewswire
3 months ago
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
Compare GRTS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GRTS Gritstone bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.